The Motion: PDE5 Inhibitors Will Have a Significant Role in the Treatment of BPH

European Urology

Volumn 52, Issue 5, 2007, Pages 1523-1527

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RHO KINASE; SILDENAFIL; TADALAFIL; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; UROFLOWMETRY; DRUG ANTAGONISM; MALE; MICTURITION DISORDER; REVIEW; TREATMENT OUTCOME;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATIC HYPERPLASIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME; URINATION DISORDERS;

EID: 34548859498     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.08.025     Document Type: Note

References (20)

1. R. Rosen J. Altwein P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649
2. K. McVary Urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology BJU Int 97 2006 23 28
3. K. McVary C.G. Roehrborn J.C. Kaminetsky Tadalafil lowers urinary tract symptoms secondary to benign prostatic hyperplasia J Urol 177 2007 1401 1407
4. K.T. McVary W. Monig J.L. Camps Sildenafil improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double – blind trial J Urol 177 2007 1071 1077
5. S.A. Kaplan R.R. Gonzalez A.E. Te Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction Eur Urol 51 2007 1717 1723
6. G. Kramer D. Mitteregger M. Marberger Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51 2007 1202 1216
7. S. Madersbacher M. Marszalek J. Lackner P. Berger G. Schatzl The long-term outcome of medical therapy for BPH Eur Urol 51 2007 1522 1533
8. B.T. Blake-James A. Rashidian Y. Ikeda M. Emberton The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis BJU Int 99 2007 85 96
9. S. Uckert P. Hedlund K.E. Andersson M.C. Truss U. Jonas C.G. Stief Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future Eur Urol 50 2006 1194 1207
10. K. Sairam E. Kulinskaya T.A. McNicholas G.B. Boustead D.C. Hanbury Sildenafil influences lower urinary tract symptoms BJU Int 90 2002 836 839
11. J.P. Mulhall P. Guhring M. Parker C. Hopps Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction J Sex Med 3 2006 662 667
12. K.T. McVary W. Monnig J.L. Camps Jr. J.M. Young L.J. Tseng G. Gene van den Ende Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial J Urol 177 2007 1071 1077
13. R.R. Gonzalez S.A. Kaplan Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia Expert Opin Drug Metab Toxicol 2 2006 609 617
14. E.S. Waldkirch S. Uckert K. Langnase Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue Eur Urol 52 2007 495 501
15. P.J. Smet J. Jonavicius V.R. Marshall J. de Vente Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry Neuroscience 71 1996 337 348
16. A. Reitz S. Bretscher P.A. Knapp M. Muntener B. Wefer B. Schurch The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans Eur Urol 45 2004 367 373
17. S. Filippi A. Morelli P. Sandner Characterization and functional role of androgen-dependent PDE5 activity in the bladder Endocrinology 148 2007 1019 1029
18. S.N. Datta R.B. Kavia G. Gonzales C.J. Fowler Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler’s Syndrome) Eur Urol 51 2007 489 495
19. K.-E. Andersson A.J. Wein Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence Pharmacol Rev 56 2004 581 631
20. S.A. Kaplan C.G. Roehrborn E.S. Rovner M. Carlsson T. Bavendam Zhoughong Guan Tolterodine and tamsulosin for treatment of lower urinary tract symptoms and overactive bladder. A randomized controlled trial JAMA 296 2006 2319 2328